COMBINATION CANCER THERAPIES
The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.
1 . The use of a therapeutically effective amount of istiratumab in combination with an immunomodulatory agent to treat cancer in a human patient, where the immunomodulatory agent is selected from the group consisting of: (a) an agonistic anti-receptor antibody that immunospecifically binds human OX40, CD40, GITR, CD27, ICOS, or 4-1BB; (b) an antagonistic anti-receptor antibody that immunospecifically binds human CTLA-4, PD-1, PD-L1, TIM-3, BTLA, VISTA, LAG-3, KIR, CD47, CD25, B7-H3, or B7-H4; and (c) an anti-ligand antibody that blocks function of IL-6, IL-10, TGFβ, angiopoetin-2, VEGF, IL-17, IL-23, or TNFα.
2 . The use of claim 1 , wherein the cancer is selected from the group consisting of: colorectal cancer, melanoma, B-cell lymphoma and fibrosarcoma.
3 . The use of claim 1 or 2 , wherein the human patient does not have detectable free IGF-1 in serum prior to administration of the istiratumab to treat the cancer.
4 . The use of any one of claims 1 - 3 , wherein the PD-1 blocking antibody is nivolumab.
5 . The use of any one of claims 1 - 4 , wherein the cancer is melanoma.
6 . The use of any one of claims 1 - 5 , wherein the human patient does not have an active autoimmune condition prior to the administration of the istiratumab.
7 . The use of any one of claims 1 - 6 , wherein the istiratumab is administered once every two weeks to treat the cancer in the human patient.
8 . The use of any one of claims 1 - 7 , wherein the istiratumab is administered at a dose of 40 mg/kg or 2.8 g once every two weeks.
9 . The use of any one of claims 1 - 8 , wherein the PD-1 blocking antibody is administered once every 2 weeks at a dose of 3 mg/kg.
10 . The use of any one of claims 1 - 3 and 5 - 8 , wherein the anti-CTLA-4 antibody is ipilimumab or tremelimumab.
11 . The use of any one of claims 1 - 9 , wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab.
12 . The use of any one of claims 1 - 3 and 5 - 8 , wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, durvalumab, and avelumab.
13 . The use of claim 12 , wherein the anti-PD-L1 antibody is atezolizumab.
14 . The use of any one of claims 1 - 3 and 5 - 8 , wherein the immunomodulatory agent is lirilumab.
15 . The use of any one of claims 1 - 3 , 5 - 8 , and 10 , wherein immunomodulatory agent is an anti-CTLA-4 antibody, and the cancer is melanoma.
16 . The use of a therapeutically effective amount of istiratumab as an immune-oncology monotherapy to treat colorectal cancer, melanoma, B-cell lymphoma or fibrosarcoma cancer in a human patient without a diagnosed active autoimmune condition.
17 . The use of claim 16 , wherein the human patient has immune cells expressing IGF-1R and ErbB3.
18 . The use of any one of claims 15 - 17 , wherein the therapeutically effective amount of istiratumab is administered once every week or once every two weeks.
19 . The use of any one of claims 15 - 18 , wherein the therapeutically effective amount of istiratumab is a fixed dose of 2.8 g, 2.24 g, or 1.96 g or 40 mg/kg administered once every two weeks.
20 . The use of an antineoplastic therapy consisting of a therapeutically effective amount of istiratumab in combination with an immunomodulatory agent selected from the group consisting of: an anti-PD-L1 antibody, an anti-CTLA-4 antibody and an anti-PD-1 antibody, to treat colorectal cancer, melanoma, B-cell lymphoma or fibrosarcoma cancer in a human patient having immune cells expressing IGF-1R and ErbB3 and without a diagnosed active autoimmune condition.
21 . The use of claim 20 , wherein the human patient has Treg cells expressing IGF-1R and ErbB3.
22 . The use of claim 20 or 21 , wherein the therapeutically effective amount of istiratumab is administered once every week or once every two weeks.
23 . The use of any one of claims 20 - 22 , wherein the therapeutically effective amount of istiratumab is a fixed dose of 2.8 g, 2.24 g, or 1.96 g or 40 mg/kg administered once every two weeks.
24 . The use of any one of claims 16 - 23 , wherein the patient has cancer cells that do not express at least one of IGF-1R and ErbB3.
25 . The use of a therapeutically effective amount of istiratumab as an immune-oncology to treat a cancer that does not express at least one of IGF-1R and ErbB3 in a human patient without a diagnosed active autoimmune condition, and having immune cells expressing IGF-1R and ErbB3.
26 . The use of claim 16 , wherein the cancer is selected from the group consisting of: colorectal cancer, melanoma, B-cell lymphoma and fibrosarcoma cancer.
27 . The use of any one of claims 24 - 26 , wherein the therapeutically effective amount of istiratumab is administered as a monotherapy, without another immunomodulatory agent, once every week or once every two weeks.
28 . The use of claim 27 , wherein the therapeutically effective amount of istiratumab is a fixed dose of 2.8 g, 2.24 g, or 1.96 g or 40 mg/kg administered once every two weeks.
29 . The use of an antineoplastic therapy consisting of istiratumab in combination with an immunomodulatory agent selected from the group consisting of: an anti-PD-L1 antibody, an anti-CTLA-4 antibody and an anti-PD-1 antibody, to treat a cancer that does not express at least one of IGF-1R and ErbB3 in a human patient without a diagnosed active autoimmune condition, and having immune cells expressing IGF-1R and ErbB3 in a human patient without a diagnosed active autoimmune condition.
30 . The use of claim 29 , wherein the cancer is selected from the group consisting of: colorectal cancer, melanoma, B-cell lymphoma and fibrosarcoma cancer.
31 . The use of claim 29 or 30 , wherein the therapeutically effective amount of istiratumab is administered as an antineoplastic therapy consisting of istiratumab and the immunomodulatory agent, once every week or once every two weeks.
32 . The use of claim 31 , wherein the therapeutically effective amount of istiratumab is a fixed dose of 2.8 g, 2.24 g, or 1.96 g or 40 mg/kg administered once every two weeks.